A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Phase 1
90
about 3.3 years
18+
21 sites in AZ, CA, FL +10
About this study
Researchers are testing a new treatment, CLSP-1025, for adults with solid tumors that have the p53 R175H mutation. The trial will determine the best dose of CLSP-1025 to use in people with this type of cancer.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take CLSP-1025
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Part A: Determine the maximum tolerated dose (MTD) and/or the recommended dose(s) for expansion (RDE[s]), Part B: Evaluate the Objective response rate (ORR) of CLSP-1025 as a monotherapy in HLA-selected patients with advanced solid tumors that express the p53 R175H mutation
Secondary: Disease Control Rate, Duration of response (DOR), Half-life (t1/2) of CLSP-1025, Maximum plasma concentration (Cmax) of CLSP-1025, Number of patients with treatment-emergent adverse events, as assessed by CTCAE, v5.0, Number of patients with treatment-related adverse events, as assessed by CTCAE, v5.0, Overall Survival (OS), Part A: Objective Response Rate (ORR)
Oncology, Gastroenterology